Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor

20 Jan 2023

Abstract excerpt

Abstract SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated diseases. A phase I, first‐in‐human, double‐blind, randomized, placebo‐controlled, dose‐escalation trial of single and multiple doses of SAR445088 was conducted in 93 healthy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Erythrocyte Function and Pathophysiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36661084
DOI: 10.1111/cts.13481

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorPMID 36661084Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside interventionSemantic proximity Read ↗

Compstatins: the dawn of clinical C3-targeted complement inhibitionSemantic proximity Read ↗

A study of the molecular pharmacological properties of C5a and C5a des Arg : defining their biased agonist profile and contrasting biological functionSemantic proximity Read ↗

A First-in-human phase I study of an innovative selective inhibitor targeting coagulation factor XI/XIa in healthy volunteersSemantic proximity Read ↗

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsSemantic proximity Read ↗

The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonistSemantic proximity Read ↗

Mechanistic insights into complement pathway inhibition by CR1 domain duplicationSemantic proximity Read ↗

A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH.Semantic proximity Read ↗

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BSemantic proximity Read ↗

Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid.Semantic proximity Read ↗

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.